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Abstract
An irreversible extrapyramidal syndrome occurs in man after intravenous abuse of “homemade” methcathinone (ephedrone, 
Mcat) that is contaminated with manganese (Mn) and is accompanied by altered basal ganglia function. Both Mcat and Mn 
can cause alterations in nigrostriatal function but it remains unknown whether the effects of the ‘homemade’ drug seen in 
man are due to Mcat or to Mn or to a combination of both. To determine how toxicity occurs, we have investigated the effects 
of 4-week intraperitoneal administration of Mn (30 mg/kg t.i.d) and Mcat (100 mg/kg t.i.d.) given alone, on the nigrostriatal 
function in male C57BL6 mice. The effects were compared to those of the ‘homemade’ mixture which contained about 
7 mg/kg of Mn and 100 mg/kg of Mcat. Motor function, nigral dopaminergic cell number and markers of pre- and postsyn-
aptic dopaminergic neuronal integrity including SPECT analysis were assessed. All three treatments had similar effects on 
motor behavior and neuronal markers. All decreased motor activity and induced tyrosine hydroxylase positive cell loss in 
the substantia nigra. All reduced 123I-epidepride binding to D2 receptors in the striatum. Vesicular monoamine transporter 2 
(VMAT2) binding was not altered by any drug treatment. However, Mcat treatment alone decreased levels of the dopamine 
transporter (DAT) and Mn alone reduced GAD immunoreactivity in the striatum. These data suggest that both Mcat and Mn 
alone could contribute to the neuronal damage caused by the ‘homemade’ mixture but that both produce additional changes 
that contribute to the extrapyramidal syndrome seen in man.
Keywords Methcathinone · Ephedrone · Manganese · Nigrostriatal damage
Background
Abuse of a ‘homemade’ version of the psychostimulant drug 
methcathinone (Mcat) causes a persistent and disabling 
extrapyramidal syndrome (Sikk et al. 2011, 2013; Stepens 
et al. 2014).This shares some common features with Par-
kinson’s disease, but has distinct symptoms including early 
falls, dystonia, severe dysarthria, and a poor response to 
l-DOPA treatment (Sikk et al. 2011). The precise cause of 
the neurological symptoms remains unknown. However, the 
recipe for producing ‘homemade’ Mcat involves the oxi-
dation of pseudoephedrine using potassium permanganate. 
This produces a solution containing high levels of both Mcat 
and manganese (Mn) which is then injected intravenously 
on multiple occasions each day (Sikk et al. 2007). The neu-
rological syndrome that appears in man is accompanied by 
Mn deposition in the basal ganglia and altered basal ganglia 
function as assessed by abnormal fluorodeoxyglucose (FDG) 
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uptake (Sikk et al. 2013; Stepens et al. 2014) and decreased 
striatal D2 receptor binding density (Kessler et al. 2003) 
shown by MRI and PET investigations.
To date the development of neurological syndrome pro-
duced by ‘homemade’ Mcat abuse has been associated 
with Mn toxicity based on the known effects of exposure 
to the metal in man (Taba 2013). Mn impairs the release of 
dopamine without causing a significant loss of nigro-stri-
atal dopaminergic neurons (Guilarte 2013). This would fit 
with the fact that ‘homemade’ Mcat produced using sodium 
dichromate as the oxidizing agent, does not appear to have 
the same toxic effects. However, Mcat itself also causes stri-
atal dopamine release and inhibits its reuptake after both 
acute and chronic administration (Cozzi et al. 2013) and its 
potential toxicity on longer term administration is unclear. 
This raises the possibility that effects of ‘homemade’ Mcat 
seen in man are either due to Mn toxicity or to the actions 
of Mcat or to a synergistic interaction. This has never previ-
ously been investigated.
In this investigation, we have studied the effects of long-
term administration of Mcat or Mn to mice. Importantly, we 
have compared the effects to those produced by ‘homemade’ 
Mcat produced according to the recipe used by drug addicts 
in their kitchens and that contains the same ratio of Mcat 
to Mn found in the illegal drug mixture. We investigated 
alterations in motor performance and the effects on dopa-
minergic neurons in basal ganglia, and changes in postsyn-
aptic dopamine D2 receptor binding SPECT analysis with 
123I-epidepride.
Materials and methods
Animals
Male C57BL6 mice (Harlan Laboratories, The Netherlands) 
aged 8 weeks were housed in groups of 7–8 in controlled 
room conditions (temperature, humidity) at 12 h/12 h light-
ing scheme. In total 60 animals were used for the experi-
ment. They had free access to water and food. The feed was 
R-70 (LabFor, Sweden) containing 68 mg of Mn per kilo-
gram of feed. Animals were weighed once a week.
Substances
The following substances were used:
1. Mcat—racemic methcathinone ((RS)-2-(methylamino)-
1-phenyl-propan-1-one, Sigma-Aldrich) powder was 
dissolved in sterile 0.9% saline (B. Braun, Germany).
2. Mn—manganese chloride  (MnCl2) was dissolved in ster-
ile 0.9% saline.
3. Mcat/Mn—the drug mixture was prepared in a manner 
closely resembling the methods used by drug abusers 
and previously described in an article by Sikk et al. 
(2007): 48 pills containing 60 mg pseudoephedrine 
hydrochloride (Sudafed, GSK) were stripped of the coat-
ing layer and dissolved in 260 ml of boiling tap water. 
4 g of potassium permanganate  (KMnO4) and 4.8 ml 
of 30% vinegar were added to complete the reaction. 
The resulting mixture was filtered through filter paper, 
cooled rapidly to room temperature and stored at + 4 °C 
to be used as required. A fresh solution was prepared 
each week.
4. Control—sterile 0.9% saline.
Mcat and Mn content of the drug mixture, as prepared, 
was measured by a mass spectrometric analysis as published 
before (Asser et al. 2016). In the drug mixture the aver-
age Mcat content was 9.87 mg/ml (range 8.82–10.54 mg/
ml) and the average Mn content was 0.688 mg/ml. Animals 
were dosed intraperitoneally with Mcat, Mn, Mcat/Mn or 
saline three times a day, 7 days a week for a total duration 
of 4 weeks. The substances were dissolved with sterile 0.9% 
saline to deliver a dose of 100 mg/kg of pure methcathinone 
in the Mcat group, 30 mg/kg of manganese chloride in the 
Mn group, and 100 mg/kg of methcathinone together with 
7 mg/kg of Mn in the Mcat/Mn group. The injection volume 
was 0.1 ml per 10 g of body weight. Control group animals 
were intraperitoneally injected with 0.2 ml of 0.9% sterile 
saline.
Behavioral testing
Motility box testing was performed pretreatment, and at 2 
and 4 weeks. Animals (all groups n = 15) were placed sin-
gly into plexiglass photoelectric motility boxes measuring 
448 × 448 × 450 mm. Covered distance, time in the center 
area of the box and time in motion were recorded during a 
period of 30 min immediately after treatment. Group aver-
ages were calculated and used for statistical analysis.
SPECT study
SPECT imaging was carried out after 4 weeks of treatment 
following the completion of behavioral testing. 48 h after 
the last drug injection animals (Mcat n = 5, Mn n = 4, Mcat/
Mn n = 5, control n = 5, selected randomly from respective 
groups) were anesthetized with isoflurane (4% for induc-
tion, 2% for maintenance) in 0.8 l/min medical oxygen as a 
carrier gas. 123I-epidepride (29.9 ± 5.9 MBq; MAP Medical 
Technologies, Tikkakoski, Finland) in < 200 µl was injected 
intravenously. Radioactivity in the syringe was measured 
pre- and post-injection with a dose calibrator (CRC-25R, 
Capintec Inc., NJ, USA).
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SPECT/CT imaging was performed with four-headed 
small animal scanner NanoSPECT/CT (Bioscan Inc., DC, 
USA), outfitted with 1.0 mm multi-pinhole mouse apertures. 
The body temperature was maintained warm throughout the 
study using a heated animal bed (Minerve, France). Brain 
SPECT images were acquired 50 min post-injection in 20 
projections using time per projection of 270 s resulting in 
total acquisition time of 23 min. CT imaging was carried 
out with 45 kVp tube voltage in 180 projections. SPECT 
images were reconstructed with HiSPECT NG software 
(Scivis GmbH, Germany) and fused with CT datasets using 
InVivoScope software (Bioscan).
Reconstructed SPECT images were reoriented and ana-
lyzed with InVivoScope software using CT data as a ref-
erence. Three-dimensional volume of interest (VOI) was 
defined around the striatum and cerebellar regions cor-
responding to D2 receptor-rich and D2 receptor-devoid 
123I-epidepride brain uptake, respectively. Specific to non-
specific binding ratios (BP) were calculated using the for-
mula: [(counts per voxel in striatum)−(counts per voxel in 
cerebellum)/(counts per voxel in cerebellum)]. Two inde-
pendent researchers performed VOI analysis.
Perfusion and dissection of animals
After the completion of the in vivo 123I-epidepride SPECT 
study and behavioral testing, all experimental animals were 
euthanized with an intraperitoneal injection of 300 mg/kg 
thiopental sodium to dissect brain tissues. After the loss of 
reflexes, a sternotomy was done and the animals were per-
fused through the left ventricle of the heart with 0.1 M PBS 
(pH 7.4) followed by 0.1 M PBS containing 4% PFA (pH 
7.4). Following dissection, brains were removed and further 
post-fixed in 4% PFA solution for three days at room temper-
ature and cryoprotected in 0.1 M PBS (pH 7.4) containing 
30% sucrose until the tissues sank. Following cryoprotec-
tion, the tissues were flash-frozen in liquid nitrogen on dry 
ice and stored at − 70 °C for further study.
Immunohistochemical studies
The frozen brain tissue was cut into 20 μm sections using 
a cryostat (Bright Instrument Co. Ltd, UK) and sections at 
the level of the striatum and substantia nigra pars compacta 
(SNpc) were stored in 0.1 M PBS (pH 7.4) containing 0.05% 
sodium azide at 4 °C as free-floating sections until use.
To determine the dopaminergic neuronal and terminal 
loss as well as the expression of vesicular monoamine 
transporter type 2 (VMAT2) and glutamate decarboxylase 
(GAD 65/67), sections at the level of the SNpc and stria-
tum were stained with different antibodies by peroxidase 
immunohistochemistry. Three to four sections were stained 
in each animal. Sections were incubated with 0.3% hydrogen 
peroxidase in 0.1 M PBS (pH 7.4) to inhibit endogenous 
peroxidase activity, washed in 0.05% Triton-X-100/PBS and 
incubated in 20% normal goat serum (NGS)/0.05% Triton-
X-100/PBS or 1% bovine serum albumin (BSA)/0.05% Tri-
ton-X-100/PBS to block non-specific binding. Sections were 
further incubated overnight with primary antibodies against 
tyrosine hydroxylase (TH; rabbit, 1:500; Pel-Freez Biologi-
cals, USA), DAT (rabbit, 1:500; Millipore, UK) or VMAT2 
(rabbit, 1:200; Millipore, UK) and glutamate decarboxylase 
(GAD 65/67; rabbit, 1:500; Millipore, UK). The next day 
sections were incubated with anti-rabbit biotinylated IgG 
secondary antibody (diluted 1:200; Vector Laboratories, 
UK), avidin–biotin complex (Vector Laboratories, UK) and 
visualized with 0.05% 3,3′-diaminobenzidine and 0.05% 
hydrogen peroxide. Sections were then mounted onto poly-
ethylene-coated slides (Menzel GmbH & Co KG, Germany), 
dehydrated in graded ethanol (70%, 98% and 100%), defatted 
in Histoclear (Fisher Scientific, UK) and cover slipped with 
DePeX mounting medium (VWR Internationals, UK).
Cell counting
An Axioskop 40 and AxioCam HRc Rev.3 camera (Both 
from Carl Zeiss, Germany) were used to take photomicro-
graphs of TH immunostained sections with the AxioVision 
4.8 Microscopy Software. The number of TH-immunoreac-
tive cells was determined in the three to four adjacent SNpc 
sections under magnification 20× in the microscope as 
described previously by Iravani et al. (2005). Previously we 
have shown that the counting of dopaminergic neurons at the 
third cranial nerve provide a reliable anatomical landmark 
that reflects the extent of cell loss through the entire SNpc 
(Iravani et al. 2002; Bukhatwa et al. 2009), suggesting that 
the cell counting at the level of third cranial nerve is an alter-
native method of determining cell loss in comparison with 
stereological counting. As each section had 20 μm thick-
ness, all TH immunoreactive cells were counted by changing 
the magnification of the microscope. Cells that appeared 
severely deformed were excluded from the counting. Healthy 
TH-positive dopaminergic neurons had a bipolar shape with 
dendrites.
The expression level of DAT, GAD 65/67 and VMAT2 in 
the striatum was determined in the method based on Iravani 
et al. (2005). Photomicrographs of the whole striatal sections 
were taken by Canon 500D digital camera in three adja-
cent sections (+ 0.50–0.62 mm anterior to Bregma) in each 
animal. Images were analyzed using the Image J software. 
Relative optical density was assessed for the whole striatum 
in each animal. Background reading was made from the cor-
pus callosum and anterior commissure. This compensates 
for slight variations in the intensity of TH immunostaining. 
Differences in density between the striatum and corpus cal-
losum were taken as the expression levels of each marker.
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Statistical analysis
Means of three sections were calculated for all measured 
parameters and one-way ANOVA with Newman–Keul’s 
multiple comparison tests were used for analysis. Two-way 
ANOVA was used for the analysis of behavioral data. p val-
ues of < 0.05 were considered statistically significant. Sta-
tistical analysis was carried out with GraphPad Prism 6.0 
(GraphPad Software, USA).
Results
Throughout the drug treatment period both Mcat and Mcat/
Mn stimulated motor activity, with activity increasing com-
pared to control immediately after dosing. In the motility 
box, distance covered, time in motion and time spent on rear 
feet were significantly decreased compared to the control 
group (Table 1). After 4 weeks of drug treatment a clear 
suppression in overall motor activity of animals treated with 
Mcat, Mn, or Mcat/Mn was found.
Weight of the animals did not change significantly during 
the 4 weeks. The mean weight by treatment groups were 
control 22.8 g (95% CI 21.9–23.7), Mcat/Mn 23.3 g (95% 
CI 22.4–24.2), Mcat 22.7 g (95% CI 21.5–23.9) and Mn 
22.1 g (95% CI 21.2–23.1) at baseline and control 25.2 g 
(95% CI 24.5–25.9), Mcat/Mn 25.2 g (95% CI 23.8–26.7), 
Mcat 24.3 g (95% CI 23.1–25.5) and Mn 22.2 g (95% CI 
21.4–23.1), respectively, by the end of the 4 week treatment 
period.
SPECT imaging demonstrated a significant decrease in 
specific to nonspecific epidepride binding ratio in Mcat 
(1.85; 95% CI 0.9–2.7), Mn (1.61; 95% CI 0.7–2.5) and 
Mcat/Mn (2.06; 95% CI 1.5–2.7) groups compared to the 
controls (mean 7.22; 95% CI 3.7–10.8; details shown in 
Fig. 1, left). Representative SPECT images of the anatomi-
cal regions are shown in Fig. 1 (right panels).
Results of the immunohistochemical staining studies 
are summarized on Figs. 2 and 3. TH positive cell count-
ing showed a significant decrease of overall cell density in 
the SN in Mcat, Mn and Mcat/Mn treated animals (Fig. 2). 
There was a decrease in DAT expression in Mcat-treated ani-
mals as compared to the control group (Fig. 3). GAD65/67 
staining was reduced by the administration of Mn alone. 
There was no change in VMAT2 expression following any 
of the treatments.
Discussion
We analyzed the effects of two potentially toxic compounds, 
Mcat and Mn, in a homemade drug based on pseudoephed-
rine conversion. While Mcat is the desired oxidation prod-
uct, Mn is generated in a free form from a major ingredient, 
potassium permanganate. The onset of a parkinsonian syn-
drome in individuals abusing this cocktail has previously 
been attributed to Mn toxicity since occupational exposure 
to the metal is associated with the occurrence of similar 
motor symptoms (Lucchini et al. 2009; Sikk et al. 2007). 
In addition, a similarly acting Mcat mixture prepared using 
sodium dichromate, instead of potassium permanganate does 
not lead to evident neurological sequelae based on short term 
exposure (Emerson and Cisek 1993). However, neither the 
conclusion that Mn alone is responsible for the syndrome 
occurring in man nor the potential role played by Mcat has 
been tested. We now show in mice that both components of 
this drug cocktail, Mn and Mcat, contribute to its toxicity.
The abovementioned syndrome in itself, although devas-
tating for the affected population, is less known throughout 
the world. At the same time, the use of methcathinone is 
part of a larger epidemiological trend of synthetic cathinone 
Table 1  Results of motility box testing
Motion was measured for a 30 min period immediately after the injection. All values are group means with 95% CI as compared to the control 
group at the same time point
*p < 0.05; **p < 0.01; ***p < 0.001 compared to control
Distance (m) Time in motion (s) Time on rear feet (s)
Baseline 2 weeks 4 weeks Baseline 2 weeks 4 weeks Baseline 2 weeks 4 weeks
Control 
(N = 15)
103.2 
(94.9–111.5)
84.4 (77.2–
91.7)
85.3 (77.3–
93.4)
623.4 (582.8–
664.0)
549.8 (512.7–
586.8)
553.4 (510.2–
596.5)
150.9 (129.0–
172.8)
144.2 (111.1–
177.3)
114.9 
(94.8–135.0)
Mcat 
(N = 15)
104.9 
(97.6–112.2)
101.6 
(79.7–123.5)
38.8 (22.2–
55.4)***
624.9 (584.9–
665.0)
600.2 (481.9–
718.5)
260.4 (160.8–
360.0)***
159.3 (147.1–
171.6)
121.8 (88.55–
155.1)
52.8 (19.5–
86.11)**
Mn (N = 15) 92.0 (81.5–
102.4)
68.4 (57.1–
79.7)*
63.5 (52.7–
74.3)**
564.9 (505.9–
623.8)
448.5 (379.5–
517.6)**
419.5 349.8–
489.1)**
126.3 (108.2–
144.3)
74.5 (53.8–
95.1)***
62.6 (43.6–
81.7)***
Mcat/Mn 
(N = 15)
108.4 
(96.9–119.9)
110.3 (84.6–
135.9)**
62.3 (52.0–
72.6)***
648.5 (588.6–
708.5)
655.6 (529.8–
781.5)*
413.7 
(351.3–476.2) 
***
158.3 (130.8–
185.9)
123.3 
(99.4–147.1)
74.9 (47.5–
102.2)
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abuse. The mixture of manganese and methcathinone, also 
termed ephedrone in literature, is mainly reported as case 
series or case reports and larger studies are lacking (Sikk 
and Taba 2015).
Administration of Mcat, Mn and a “home-made” mix-
ture containing the two led to similar and consistent changes 
in motor function. As expected, there was an immediate 
acute response to each injection of Mcat alone or in com-
bination with Mn over the 4-week period, in the form of 
stereotypical movements lasting 30–60 min. This effect 
has been described in relation to Mcat as well as other 
psychostimulants (Anneken et al. 2017). But importantly, 
both components (Mcat and Mn), alone or in combination, 
equally suppressed overall motor activity by the end of the 
4-week treatment period as shown in the motility box. An 
interesting observation was that this effect was, if anything, 
more evident with Mcat alone than with Mn alone or Mn in 
combination with Mcat. Overall, the changes observed in 
Fig. 1  Binding ratio of 123I-epidepride uptake and SPECT images of 
mouse striatum. SPECT imaging demonstrates a significant decrease 
in epidepride binding in all treatment groups. a Mean binding ratios 
with 95% CI values of controls (N = 5), Mcat (N = 5), Mn (N = 4); 
Mcat/Mn (N = 5). **p < 0.01 compared to control (Newman–Keul’s 
test). A single illustrative SPECT image from each group b control; 
c Mcat; d Mn; e Mcat/Mn. The red crosshair is placed on the striatum
Fig. 2  Effect of Mcat, Mn and Mcat/Mn administration on the num-
ber of TH-positive dopaminergic neurons in the SNpc. Immunohis-
tochemical staining shows a loss of dopaminergic cells in the SNpc 
as demonstrated by a decrease in the number of TH positive stained 
neurons per section. a Data are presented as mean with 95% CI. For 
controls N = 7, Mcat (N = 12), Mn (N = 10) and Mcat/Mn (N = 12). 
***p < 0.001 compared to the naïve animals (Newman–Keul’s). b–e 
An illustrative image of the TH stained cells from a single animal in 
each group is shown on the right. b Control; c Mcat; d Mn; e Mcat/
Mn
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motor function reflect the development of the extrapyramidal 
syndrome as seen in man. The described locomotor changes 
are in concordance with previously published literature (see 
the excellent review by Angoa-Perez et al. (2017).
The alterations in motor function and a marked decrease 
in the number of TH immunoreactive cells in substantia 
nigra is in good correlation. The decrease in cell number 
occurred after the administration of Mn or Mcat or a com-
bination of the two. A similar change following Mn admin-
istration was described previously in mice (Stanwood et al. 
2009) but this is the first time that this has been shown fol-
lowing Mcat treatment. The decrease presumably reflects 
a loss of dopaminergic cell bodies although a reduction in 
TH expression cannot be excluded. Psychostimulants are 
known to be directly toxic to nigral dopaminergic cells. For 
example, Ares-Santos et al. (2014) demonstrated a marked 
reduction in the number of nigral dopaminergic neurons 
together with changes in locomotor activity in response to 
methamphetamine administration. The overall conclusion 
from the examination of nigral tissue, would be that both Mn 
and Mcat exert toxicity and that this effect is reflected in the 
combination of these drugs and explains the persistence of 
the motor deficits seen in man.
More puzzling are the changes in the markers of presyn-
aptic function of dopaminergic neurons in the striatum. It 
might have been expected that there would be reductions 
in VMAT2 and DAT that reflected the loss of nigral dopa-
minergic cells, but this was not the case. No changes in 
VMAT2 occurred in any treatment group and only Mcat 
given alone decreased DAT expression. These findings sug-
gest that presynaptic dopaminergic function was occurring 
relatively normally despite substantial nigral cell loss. The 
explanation may be that, at the timepoints studied, there was 
on-going nigral TH positive cell degeneration that had yet to 
be reflected in changes in striatal markers. Alternatively, it 
may be that remaining dopaminergic terminals in the stria-
tum have upregulated levels of VMAT2 and DAT to com-
pensate for the losses that had already occurred. Why DAT 
should only be decreased by Mcat treatment while there is 
no effect of a combination of Mcat and Mn is a subject for 
further investigation. If we hypothesize that the toxicity of 
Mn is preferentially postsynaptic (e.g. GABA neuron) and 
that of Mcat presynaptic (dopamine neurons), the dose dif-
ferences may also become meaningful. Doses in the home-
made mixture may simply be too low to cause measurable 
changes. Mn alone has been shown to alter DAT functioning. 
A study by Roth et al. (2013) for example suggests that Mn 
induces DAT internalization and thus leads to disruption 
of dopamine signaling. However, this situation reflects the 
results of SPECT imaging studies in patients abusing the 
Mcat and Mn cocktail where presynaptic markers were unal-
tered despite the presence of marked neurological symptoms 
(Sikk et al. 2010).
Post-synaptic changes in  I123epidepride binding to post-
synaptic D2 receptors in the striatum on SPECT imaging 
were marked in animals treated with Mcat alone, Mn alone 
or a combination of the two. We have assumed that the 
changes in  I123-epidepride binding represent a decrease in 
receptor number and not competition with Mcat for recep-
tor occupancy. Mcat should be cleared from the body by the 
time of SPECT scanning based on its plasma half-life. The 
psychomotor effects of another closely related derivative of 
Mcat, mephedrone, can be measured for 2 h after administra-
tion but its plasma concentrations become undetectable 5 h 
after intravenous administration (Martinez-Clemente et al. 
2013). In addition, 123I-epidepride has such a high affinity for 
D2 receptors (Km about 50 pM) that Mcat, having a much 
lower affinity (micromolar), would be unlikely to displace it 
(Tibbo et al. 1997; Kornhuber et al. 1995). Presuming this 
to be the case, there are two potential explanations for these 
findings. The first would be that there is downregulation of 
post-synaptic D2 receptors reflected in decreased numbers 
of epidepride binding sites as a result of receptor internaliza-
tion. Such a decrease would lead to decreased motor func-
tion as previously observed in mice after D2 receptor block 
or absence (Klinker et al. 2013). The alternative explanation 
is that there is a loss of striatal cells bearing D2 receptors 
as a result of the toxicity of Mcat and Mn. This would be 
consistent with previous studies that have specifically inves-
tigated the toxic actions of Mn (Stanwood et al. 2009). D2 
receptor bearing interneurons are mostly GABAergic but 
also cholinergic and glutamatergic neurons are important. 
We found decreased GAD, a marker of GABA neurons, only 
in the Mn group. The striatal cells that have D2 receptors on 
Fig. 3  Expression levels of DAT, VMAT2 and GAD 65/67 in the 
striatum in Mcat-, Mn- and Mcat/Mn-treated animals. Immunostain-
ing of the striatum was measured as optical density using Image J. 
***p < 0.001 compared to control animals (Newman–Keul’s). Control 
(N = 10), Mcat (N = 6), Mn (N = 4) and Mcat/Mn (N = 7)
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their cell bodies are largely making up the indirect output 
pathway to the external segment of the globus pallidus. Cell 
loss would disrupt the striato-thalamo-cortical loop control-
ling voluntary movement and explain the changes seen in 
motor function in both man and animals. A strong argument 
for the importance of postsynaptic damage can be derived 
from the clinical poor l-DOPA response of the patients. If 
there is a substantial damage of the cells bearing D2 recep-
tors, the target of l-DOPA therapy is reduced.
One of the main limitations of the present study includes 
the timing of experiments (locomotor effects, immunohisto-
chemical and SPECT studies). It could be argued that a longer 
experiment duration could have resulted in more significant 
changes. While this is true, it was our goal to demonstrate 
the presence of abovementioned alterations rather than quan-
tify them in detail. In addition, originating from the clinical 
practice, there are reports of patients suffering from markedly 
severe symptoms after only a short period of using the drug.
Conclusions
Based on our results, we conclude that both components of 
the Mcat and Mn cocktail can exert toxic actions that disrupt 
dopaminergic function and striatal output that leads to the 
generation of an extrapyramidal syndrome. While both lead 
to altered function of the basal ganglia, it is in all probabil-
ity the addictive properties of Mcat that drive the frequent 
daily abuse of the cocktail that then inflicts cellular damage. 
These findings are of importance as despite the best efforts, 
there has been no detailed examination of post-mortem brain 
material from the addict population that would have allowed 
the uncovering of pathophysiological mechanisms responsi-
ble for their neurological symptoms to be uncovered.
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